Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Aucatzyl Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Aucatzyl (obecabtagene autoleucel) — Medical Prior Authorization / Coverage Criteria

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs prior authorization and step-edit requests for Aucatzyl (obecabtagene autoleucel) for AvMed members, specifying required documentation, clinical eligibility, dosing, and site-of-care information for providers requesting coverage.

    Policy Summary
    PayerAvMed
    PolicyAucatzyl (obecabtagene autoleucel) — Medical Prior Authorization / Coverage Criteria
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization via AvMed form faxed to 1-877-535-1391 with a hand-signed prescriber signature and complete supporting documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    onetreatment course allowed per lifetime
    410 x 10^6total recommended dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+
    minimum age
    Day 1 & Day 10split-dose schedule

    Coverage Criteria for Aucatzyl (obecabtagene autoleucel)

    Initial therapy/Eligibility

    Covered when ALL of the following are met:

    Age: Member is 18 years of age or older>=18 years
    Provider and facility qualifications: Provider is an oncologist and administering facility providers have received training on management of cytokine release syndrome (CRS) and neurological toxicities
    Prior CAR-T therapy: Member has NOT received prior CAR-T therapy

    Anti-CD19 therapy and re-biopsy

    • Anti-CD19 history: Either no prior anti-CD19 therapy OR prior anti-CD19 with confirmed CD19-positive disease on re-biopsy
    Therapy use: Medication will be used as single agent therapy (not counting lymphodepleting or additional chemotherapy while awaiting manufacture)
    Infection screening: Member has been screened for HBV, HCV, and HIV prior to leukapheresis in accordance with clinical guidelines

    Documentation required

    Active infection: Member does NOT have a clinically significant active systemic infection or inflammatory disorder
    Infection prophylaxis: Prophylaxis for infection has been followed according to local guidelines
    Live vaccines: Member has NOT received live vaccines within 6 weeks prior to start of lymphodepleting chemotherapy, will not receive live vaccines during treatment, and will not receive live vaccines until immune recovery following treatment6 weeks
    Diagnosis: Member has a diagnosis of relapsed or refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Philadelphia status: Member's condition meets ONE of: Philadelphia Chromosome (Ph)-Positive disease with prior TKI therapy OR Philadelphia Chromosome (Ph)-Negative disease

    Either Ph+ with prior TKI or Ph- acceptable

    Dose determination: Bone marrow blast percentage assessed and documented to determine dosing per specified regimen (different Day 1 and Day 10 doses depending on >20% vs ≤20%)Bone marrow blast >20% or ≤20%

    Laboratory documentation required

    Coverage will be provided for one treatment course and may NOT be renewed. This policy allows a single lifetime treatment (one dose per lifetime) of Aucatzyl (obecabtagene autoleucel) and does not permit additional treatment courses beyond that single authorized course.

    A member is not eligible for coverage if they have received prior CAR-T therapy. Coverage also requires meeting all clinical criteria documented on the authorization form (for example: age ≥18, appropriate provider and facility training, diagnosis of relapsed or refractory B‑cell precursor ALL, infection screening and absence of clinically significant active systemic infection, adherence to infection prophylaxis, no live vaccines within 6 weeks prior to lymphodepleting chemotherapy, and documented bone marrow blast assessment to determine dosing). Failure to meet these requirements will render the request not medically necessary.

    Coding and Billing

    Covered HCPCSHCPCSCovered
    Q2058Aucatzyl (obecabtagene autoleucel)
    inv-05: Bone Marrow Blast Percentage
    Bone marrow blast assessment> 20% or ≤ 20% determines Day 1 and Day 10 dosing; documentation of laboratory bone marrow blast percentage required
    If >20%Day 1 = 10 x 10^6; Day 10 (± 2 days) = 100 x 10^6 and 300 x 10^6
    If ≤20%Day 1 = 100 x 10^6; Day 10 (± 2 days) = 10 x 10^6 and 300 x 10^6
    Documentation requirementProvide lab results/chart notes showing bone marrow blast percentage to support dosing selection
    Clinical contextDose allocation is part of initial therapy criteria for relapsed or refractory B-cell precursor ALL

    Provider Submission & Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization required — HCPCS Q2058 (Aucatzyl ® / obecabtagene autoleucel) is a medical benefit drug and must be submitted via AvMed prior authorization before administration.

    • HCPCS: Q2058
    Documentation Required

    Samples and Prior Therapy Verification

    Samples do not satisfy preauthorization/step-edit requirements. If therapy was started with a sample, the request still requires full prior authorization documentation. Prior therapies will be verified by AvMed via pharmacy paid claims review or submitted chart notes — include documentation of prior treatments.

    • Samples do not meet preauthorization criteria
    • Previous therapies will be verified through pharmacy paid claims or chart notes

    Key Definitions

    inv-11: Split dose infusion schedule
    Split-dose scheduleTreatment administered on Day 1 and Day 10 (± 2 days)
    Dose determinationDose administered on each day is determined by the patient's bone marrow blast assessment
    Day 1 dosing optionsEither 10 x 10^6 or 100 x 10^6 depending on blast %
    Day 10 dosing componentsIncludes both a smaller dose (10 x 10^6 or 100 x 10^6) and a 300 x 10^6 dose administered on Day 10 (± 2 days)
    Scheduling toleranceDay 10 may be administered within a ±2-day window

    Dosing and Quantity Limits (Initial Therapy)

    Dosing and quantity limits

    Initial dosing and quantity limits:

    Total recommended dose is 410 x 10^6 CD19 CAR-positive viable T cells supplied in 3 to 5 infusion bags410 x 10^6
    Treatment frequency: One treatment (dose) per lifetime1 per lifetime

    Coverage will be provided for one treatment course only

    Split-dose schedule: Treatment regimen consists of a split dose infusion administered on Day 1 and Day 10 (±2 days); specific Day 1 and Day 10 doses depend on bone marrow blast percentageDay 1 and Day 10 ±2 days

    Dose allocation depends on blast percentage

    Step Therapy Rules

    StepRequirement
    1Use of samples to initiate therapy does not meet preauthorization/step edit criteria; previous therapies will be verified through pharmacy paid claims or submitted chart notes.

    Quantity Limits and Treatment Course

    inv-14: Aucatzyl total recommended CAR-positive viable T cells per treatment and lifetime limit
    Total recommended CAR-positive viable T cells410 x 10^6 total CD19 CAR-positive viable T cells supplied in 3 to 5 infusion bags
    Treatment frequency limitOne treatment (dose) per lifetime; coverage provided for one treatment course and may not be renewed
    Per-course supplySupplied across 3 to 5 infusion bags to deliver the total 410 x 10^6 cells
    Quantity limit codingMax units per dose and over time specify the 410 x 10^6 total and one lifetime treatment

    Site-of-Care Requirements

    Note

    Infusion center/site must be trained and documented

    Administer Aucatzyl at a facility with staff trained in management of cytokine release syndrome (CRS) and neurologic toxicities, and document the administering location and its NPI or DEA (or indicate specialty pharmacy if applicable).

    Background — Drug Overview

    Aucatzyl (obecabtagene autoleucel) is a CD19-directed CAR T‑cell therapy provided as a single treatment course for adults with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (ALL). The total recommended dose is 410 × 10^6 CD19 CAR‑positive viable T cells supplied in 3 to 5 infusion bags and administered as a split‑dose infusion on Day 1 and Day 10 (±2 days). The specific Day 1 and Day 10 doses are determined by documented bone marrow blast percentage: if bone marrow blast >20%, Day 1 = 10 × 10^6 and Day 10 = 100 × 10^6 and 300 × 10^6; if ≤20%, Day 1 = 100 × 10^6 and Day 10 = 10 × 10^6 and 300 × 10^6.

    Policy Summary
    PayerAvMed
    PolicyAucatzyl (obecabtagene autoleucel) — Medical Prior Authorization / Coverage Criteria
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization via AvMed form faxed to 1-877-535-1391 with a hand-signed prescriber signature and complete supporting documentation.
    SourceLink
    On This Page
    Coverage Criteria for Aucatzyl (obecabtagene autoleucel)Coding and BillingProvider Submission & Authorization RequirementsKey DefinitionsDosing and Quantity Limits (Initial Therapy)Step Therapy RulesQuantity Limits and Treatment CourseSite-of-Care RequirementsBackground — Drug Overview
    Prior Authorization

    Required Submission Information

    Complete submission must include prescriber signature (hand-signed; preprinted stamps not valid), member name, AvMed ID number, date of birth, prescriber name, office contact, phone and fax numbers, prescriber NPI, drug name/form/strength, dosing schedule, length of therapy, diagnosis and ICD code (if applicable), weight and date obtained (if applicable), and clear documentation of dosing and bone marrow blast assessment to support selected dose.

    • Prescriber signature (hand-signed; stamps not valid)
    • Member AvMed # and DOB
    • Prescriber NPI and contact phone/fax
    • Drug name/form/strength, dosing schedule, length of therapy
    • Diagnosis and ICD code (if applicable)
    • Weight and date weight obtained (if applicable)
    • Bone marrow blast percentage documentation to support dose selection
    Denial Risk

    Incomplete or Illegible Submission — Denial Risk

    Incomplete, incorrect, or illegible information — including missing labs, diagnostic reports, bone marrow blast percentage, or unclear signatures — can delay review or result in denial. For urgent reviews, contact AvMed Pre-Authorization Department per instructions if lack of treatment would seriously jeopardize life or health.

    • Missing labs or diagnostics may lead to delayed authorization or denial
    • Illegible or missing prescriber signature will invalidate request
    • Contact AvMed Pre-Authorization Department for urgent review requests
    Dose by blast %: If Bone Marrow Blast >20%: Day 1 = 10 x 10^6; Day 10 = 100 x 10^6 and 300 x 10^6. If Bone Marrow Blast ≤20%: Day 1 = 100 x 10^6; Day 10 = 10 x 10^6 and 300 x 10^6.>20% vs ≤20%

    Laboratory documentation of bone marrow blast percentage required to support selected dosing